FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for patients and health plan sponsors.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC finds PBMs excessively marked up prices on specialty drugs
Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty generic drugs,
Top three insurers reaped $7.3 billion through their drug middlemen’s markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ prescription price hikes of 1,000% or more.
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
FTC Says CVS, Cigna and UnitedHealth Abuse Middleman Role
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims
A new Federal Trade Commission (FTC) report found that the three largest Pharmacy Benefit Managers (PBMs) have taken in large ...
FTC accuses CVS, Cigna, and UnitedHealth of marking up cancer, HIV drugs
Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...